Clinical trial
Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients…
NCT00062582 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00062582 |
|---|---|
| Title | Effect of Roflumilast on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) (BY217/M2-110) |
| Official title | A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary Disease, COPD |
| Intervention type | Drug |
| Interventions | Roflumilast |
| Enrollment | 1,000 |
| Start date | Jun 1, 2003 |
| First posted | Jun 10, 2003 |
| Last update posted | Nov 23, 2016 |
| Countries | Argentina, Canada, Colombia, Mexico, Peru, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: